P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

por Gautier, A, Lowe, P, Skerjanec, A, McKernan, P, Luttringer, O, Fink, M
Publicado 2013

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis

por Xiong, Y, Wang, W, Ebling, W, Sun, H, Luttringer, O, Abrams, K, Ruperto, N, Brunner, H
Publicado 2013

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

por Gergely, P, Nuesslein-Hildesheim, B, Guerini, D, Brinkmann, V, Traebert, M, Bruns, C, Pan, S, Gray, NS, Hinterding, K, Cooke, NG, Groenewegen, A, Vitaliti, A, Sing, T, Luttringer, O, Yang, J, Gardin, A, Wang, N, Crumb, WJ, Saltzman, M, Rosenberg, M, Wallström, E
Publicado 2012